Schaeffers Research
26 Dec 2025, 15:25 UTC · 42w ago
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial
Impact · against what's priced in
Biohaven faces a significant valuation reset following the Phase 2 failure of its major depressive disorder drug. The substantial gap between current trading levels and analyst price targets suggests further downward pressure as ratings are revised to reflect the loss of a primary clinical asset.
- BHVN−0.80
No priced-in read yet
- In context
The failure of the Phase 2 trial for its major depressive disorder drug removes a key growth catalyst, likely triggering a round of bear notes to reconcile the $10.46 price with an outdated $19.80 analyst consensus.
Read from the article alone
Top 1 mover · tap to explore
